ACETAZOLAMIDE AND N-ACETYLCYSTEINE IN THE TREATMENT OF CHRONIC MOUNTAIN SICKNESS (MONGE'S DISEASE).

•Chronic mountain sickness secondary to polycythemia is a major problem in certain areas of the Andes.•Here we present a clinical trial determining if acetazolamide, n-acetylcysteine, or their combination could be of clinical benefit as determined by examining the effects on chronic mountain sickness score or hematocrit.•We confirm that acetazolamide is of benefit, likely by stimulating respiratory rate, while N-acetylcysteine had modest effects on CMS score but not on hematocrit.